Literature DB >> 23151729

Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low-dose CT.

Anat Ilivitzki1, Lea Radan, Miriam Ben-Arush, Ora Israel, Ayelet Ben-Barak.   

Abstract

BACKGROUND: Interim 18F-FDG PET helps predict outcome and tailor treatment in adults with Hodgkin disease (HD).
OBJECTIVE: The purpose of this study was to assess predictive values of interim 18F-FDG PET/CT in children with HD and to define the potential added value to interim PET of low-dose CT.
MATERIALS AND METHODS: Children were prospectively enrolled August 2002-April 2007. PET/low-dose CT was performed at staging, after 2 cycles, at the end of treatment and during follow-up (mean 45 months). Treatment was unchanged regardless of interim results. PET and low-dose CT were read independently.
RESULTS: Of 34 enrolled children (ages 3-17 years), 27 achieved complete response, 4 had progressive disease and 3 had relapse. Interim PET alone had positive and negative predictive values of 67% and 89%, respectively. Interim low-dose CT alone had positive and negative predictive values of 35% and 100%, respectively. Interim PET/CT had positive and negative predictive values of 75% and 96%, respectively.
CONCLUSIONS: Early interim PET/CT was a good predictor of outcome. Integrated PET and low-dose CT improved the predictive value in children with HD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23151729     DOI: 10.1007/s00247-012-2517-9

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  23 in total

1.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Authors:  Lale Kostakoglu; Morton Coleman; John P Leonard; Ichiei Kuji; Holly Zoe; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

2.  ABVD versus BEACOPP for Hodgkin's lymphoma.

Authors:  Peter Borchmann; Volker Diehl; Andreas Engert
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

3.  Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate.

Authors:  Jennifer M Levine; Michael Weiner; Kara M Kelly
Journal:  J Pediatr Hematol Oncol       Date:  2006-11       Impact factor: 1.289

4.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

5.  Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial.

Authors:  Christian Furth; Ingo G Steffen; Holger Amthauer; Juri Ruf; Daniel Misch; Stefan Schönberger; Carsten Kobe; Timm Denecke; Brigitte Stöver; Hubertus Hautzel; Günter Henze; Patrick Hundsdoerfer
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

6.  Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.

Authors:  Christine Mauz-Körholz; Dirk Hasenclever; Wolfgang Dörffel; Kathrin Ruschke; Tanja Pelz; Antje Voigt; Martina Stiefel; Melanie Winkler; Constanze Vilser; Karin Dieckmann; Jonas Karlén; Eva Bergsträsser; Alexander Fosså; Georg Mann; Michael Hummel; Wolfram Klapper; Harald Stein; Dirk Vordermark; Regine Kluge; Dieter Körholz
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

7.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

8.  Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

Authors:  P L Zinzani; M Tani; S Fanti; L Alinari; G Musuraca; E Marchi; V Stefoni; P Castellucci; M Fina; M Farshad; S Pileri; M Baccarani
Journal:  Ann Oncol       Date:  2006-06-09       Impact factor: 32.976

9.  The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

Authors:  Andrea Gallamini; Luigi Rigacci; Francesco Merli; Luca Nassi; Alberto Bosi; Isabella Capodanno; Stefano Luminari; Umberto Vitolo; Rosaria Sancetta; Emilio Iannitto; Livio Trentin; Caterina Stelitano; Silvia Tavera; Alberto Biggi; Antonio Castagnoli; Annibale Versari; Michele Gregianin; Ettore Pelosi; Pierfederico Torchio; Alessandro Levis
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

10.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

Authors:  Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans-Konrad Müller-Hermelink; Eckhardt Dühmke; Markus Loeffler
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

View more
  3 in total

1.  qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.

Authors:  Dirk Hasenclever; Lars Kurch; Christine Mauz-Körholz; Andreas Elsner; Thomas Georgi; Hamish Wallace; Judith Landman-Parker; Angelina Moryl-Bujakowska; Michaela Cepelová; Jonas Karlén; Ana Álvarez Fernández-Teijeiro; Andishe Attarbaschi; Alexander Fosså; Jane Pears; Andrea Hraskova; Eva Bergsträsser; Auke Beishuizen; Anne Uyttebroeck; Eckhard Schomerus; Osama Sabri; Dieter Körholz; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-07       Impact factor: 9.236

2.  Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.

Authors:  Cristina Ferrari; Artor Niccoli Asabella; Nunzio Merenda; Corinna Altini; Margherita Fanelli; Paola Muggeo; Francesco De Leonardis; Teresa Perillo; Nicola Santoro; Giuseppe Rubini
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

Review 3.  Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm.

Authors:  Ramasamy Paulmurugan; Bryan Oronsky; Chad F Brouse; Tony Reid; Susan Knox; Jan Scicinski
Journal:  Theranostics       Date:  2013-05-25       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.